FDA Watch: FDA Approves Enhanced Cologuard Cancer Test
Test maker Exact Sciences says it expects Cologuard Plus to cut false positives by more than 30 percent
Keeps You Up-to-Date on Federal & State Laws, Regulations, New Legislation, and Court Cases that Affect Your Diagnostic Lab or Pathology Practice
Test maker Exact Sciences says it expects Cologuard Plus to cut false positives by more than 30 percent
From - National Intelligence Report
Labs will find most relevant the safety issue appearing at number five on ECRI's list: Inadequate Test-Result Reporting and…
From - National Intelligence Report
Despite ongoing efforts to delay the changes to the Clinical Laboratory Fee Schedule (CLFS) directed by the Protecting Access to Medicare Act of 2014 (PAMA), the Centers for Medicare & Medicaid Services's final rule implementing the…
From - National Intelligence Report
At a time when data on cost and clinical outcomes are in high demand yet short supply, the Association for Molecular Pathology (AMP, Bethesda, Md.) is taking an in-depth look at the…